Vistagen Therapeutics, INC 10-Q quarterly reports

Vistagen Therapeutics reports increased net losses and declining cash reserves, raising going concern doubts and facing a Nasdaq minimum bid price non-compliance notice.

Vistagen Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses and R&D expenses for Q2 2025, alongside a 'substantial doubt' about its ability to continue as a going concern beyond 12 months.

Vistagen Therapeutics reported increased net losses and cash burn, raising substantial doubt about its ability to continue operations beyond the next 12 months, despite advancing its neuroscience pipeline.

Vistagen Therapeutics reports a net loss of $14.1 million for the three months ended December 31, 2024, and provides an update on its clinical-stage neuroscience programs.

Vistagen Therapeutics reports a net loss of $23.7 million for the six months ended September 30, 2024, while advancing its clinical-stage neuroscience programs.

Vistagen Therapeutics reports a net loss of $10.7 million for the first quarter of fiscal year 2025, while maintaining a strong cash position of $108.4 million.

Vistagen Therapeutics reported its financial results for the third quarter of fiscal year 2024, highlighting a significant increase in cash reserves and progress in its clinical programs.